A

AbbVie

Global biopharmaceutical company developing medicines

Senior Manager - Regulatory Affairs

Full-Time
No salary listed
Mid, Senior
Bachelor's
Maidenhead, UK
HybridThree days on-site per week, Tuesday through Thursday.
Risk & Compliance, Legal

About the job

Requirements
  • The candidate must be an experienced regulatory professional in the pharmaceutical industry with a clear understanding of the United Kingdom regulatory and submissions process.
  • The candidate must have experience as a line manager with highly developed people skills.
  • The candidate must be able to multitask, prioritize, and manage multiple projects and deadlines.
  • The candidate must be able to work effectively and collaboratively across cultures and cross-functionally.
  • The candidate must have strong diplomacy, influencing, and presentation skills.
  • The candidate must have a consultative and collaborative interpersonal style.
  • The candidate must have excellent written, verbal, and interpersonal skills in English.
  • The candidate must be able to identify compliance risks and escalate them when necessary.
  • The candidate must have a Life Sciences degree in a relevant subject area.
  • The candidate must be computer literate.
Responsibilities
  • Act as the primary Regulatory contact for the identified therapeutic area of responsibility.
  • Provide line management responsibility for a small team within UK Regulatory Affairs, including recruitment, goal setting, performance appraisal, and talent development.
  • Oversee all regulatory activities within the therapeutic area of responsibility, including maintaining licensing and contributing to Brand Team priorities.
  • Guide the team in developing robust regulatory strategies and timely submissions to the Medicines and Healthcare products Regulatory Agency, ensuring approvals, implementations, and product launches.
  • Develop and maintain relationships with Area and Affiliate members of GRS Europe and cross-functional partners to share knowledge, increase regulatory awareness, and build networks.
  • Engage externally with the Health Authority on regulatory submissions and with pharmaceutical industry trade associations as required.
  • Support the business in planning and executing product launches, acquisitions, and divestitures as required.
  • Provide guidance and recommendations on United Kingdom regulatory strategies and tactical plans throughout the product lifecycle, including clinical trial submissions, variations, paediatric investigation plans, new marketing authorization applications, and liaison with local regulatory authorities.
  • Review regulatory submissions for the UK Regulatory Affairs team in assigned areas of responsibility, correct them where necessary, and provide feedback.
  • Interact with regulatory policymakers and professional associations, including the Association of the British Pharmaceutical Industry, to gather knowledge about trends, future changes, and the current regulatory landscape in accordance with national and European Union legislation and relevant association codes, and advocate for AbbVie's interests.
  • Ensure compliance with AbbVie's policies and procedures to meet statutory, quality, and business requirements, acting as the primary regulatory contact for audits and inspections in the United Kingdom as appropriate and supporting oversight of divisional policies and procedures.
  • Ensure compliance with United Kingdom legislation for medicines, medical devices, clinical trials, and paediatric investigation plans, and maintain awareness of the Association of the British Pharmaceutical Industry code.
  • Act as the regulatory liaison with Area and local United Kingdom cross-functional teams to ensure United Kingdom strategies align with global strategies while maintaining compliance with local regulations.
  • Understand and articulate the regulatory perspective across the business, translating key regulatory decisions into their impact on products in the United Kingdom.
  • Act as lead Regulatory representative on Affiliate committees and initiatives as required.
  • Act as deputy to the United Kingdom Regulatory Affairs Managers and/or Director as required.
  • Provide leadership and direction to the United Kingdom Regulatory Therapeutic team to support implementation of regulatory product strategies, relationships with the Medicines and Healthcare products Regulatory Agency and local pharmaceutical company trade associations, process improvements, internal compliance, team consistency, individual professional development, improved capability, and upskilling.
  • Support recruitment activities as required and retain high-caliber regulatory affairs professionals.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 13th, 2026
AbbVie vs Novo Nordisk: AbbVie's $61.2B revenue growth makes it the better 2026 buy

A Motley Fool comparison of AbbVie and Novo Nordisk concludes AbbVie is the better long-term buy in 2026, even though Novo looks cheaper. AbbVie's 2025 revenue rose about 8.6% to $61.2 billion, but net income was $4.2 billion. Novo Nordisk's revenue grew 6.4% to $46.3 billion, with net income of $15.3 billion. Novo trades at 11.7 times forward earnings against AbbVie's 20.2. Analysts expect Novo's 2026 sales to fall about 3% on pricing pressure and rivalry from Eli Lilly. AbbVie is forecast to grow net income to $14.6 billion on $67.2 billion in sales, helped by its $10.9 billion Apogee Therapeutics deal and its Skyrizi and Rinvoq drugs.

Yahoo Finance
Oct 13th, 2026
AbbVie shares at $281.12 trade 43.5% below DCF fair value of $497.77 after pipeline wins

AbbVie shares have climbed to $281.12, up 9.33% in a month and 22.59% so far this year, after a run of clinical and regulatory news. Total shareholder return is 25.85% over one year. The news includes Phase 3 Crohn's disease results for SKYRIZI and RINVOQ, and FDA Breakthrough Therapy Designations for Temab-A in colorectal and lung cancer. AbbVie also released early obesity data for ABBV-295 and Phase 2 atopic dermatitis results for zumilokibart. Simply Wall St's most followed narrative puts fair value at $278.61, leaving the stock 1% overvalued. Its discounted cash flow model estimates $497.77, which would put the shares about 43.5% below fair value. Risks include tighter drug price pressure and faster than expected competition for Skyrizi and Rinvoq.

Yahoo Finance
Oct 13th, 2026
AbbVie vs Eli Lilly: Lilly's 44.7% revenue surge to $65.2B makes it the 2026 pick

A comparison of AbbVie and Eli Lilly favours Eli Lilly for long-term investors, driven by its strong weight-loss and diabetes drug franchise. Lilly's 2025 revenue rose 44.7% to $65.2 billion, with net income of $20.6 billion. AbbVie's revenue grew 8.6% to $61.2 billion, with net income of $4.2 billion, as Skyrizi and Rinvoq replace ageing Humira sales. Lilly trades at a forward price-to-earnings ratio of 33.1x, against 19.8x for AbbVie. Lilly expects 2026 revenue of up to $85.2 billion, helped by Zepbound, Mounjaro and a new pill, Foundayo. AbbVie forecasts 2026 sales of $67.2 billion and net income of $14.6 billion. It is also acquiring Apogee Therapeutics.

Finanzen.net
Oct 12th, 2026
S&P 500 stock AbbVie share: This is how much profit an investment in AbbVie 10 years ago would have generated.

S&P 500 stock AbbVie share: This is how much profit an investment in AbbVie 10 years ago would have generated. October 12, 2026, 4:00 p.m. Invested in AbbVie years ago: This is how much investors would have earned. Exactly 10 years ago today, trading in the AbbVie share took place on the NYSE. The stock ended the day at USD 61.21. With a USD 100 investment 10 years ago, investors would now have 1.634 AbbVie shares in their portfolio. Calculated using the most recent closing price from October 9, 2026 (USD 276.47), the investment would now be worth USD 451.67. That means the value of the original investment would have increased by 351.67 percent. The market value of AbbVie recently amounted to USD 487.20 billion. Please note that stock splits and dividend payments are not taken into account in the above calculation. finanzen.net editorial team Selected leveraged products on AbbVie. With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired leverage and we will show you suitable open-end products on AbbVie. | Name | Leverage | KO | Issuer | | Mini Future Long on AbbVie | 4.72 | 239.26 | Morgan Stanley | | Turbo Long on AbbVie | 4.60 | 219.21 | Morgan Stanley | | Mini Future Long on AbbVie | 4.51 | 234.17 | Morgan Stanley | | Turbo Long on AbbVie | 4.31 | 215.06 | Morgan Stanley | | Turbo Long on AbbVie | 4.05 | 210.62 | Morgan Stanley | You can obtain the base prospectus as well as the final terms and the key information documents here: MR42P0, MR2ECS, MR42NZ, MR14JZ, MN9YRD. Please also note the further information** on this advertisement. Risk notice: On average, 7 out of 10 retail investors suffer losses when trading turbo certificates. Turbo certificates are highly risky products and are not suitable for long-term investment strategies.

Yahoo Finance
Oct 11th, 2026
AbbVie's yield hits 2.6%, its lowest since 2018, but dividend growth keeps it an income pick

AbbVie's dividend yield has fallen to about 2.6%, its lowest since early 2018. The drop comes from a share price that has risen faster than the dividend, not from any cut. The drugmaker has raised its dividend for 54 consecutive years, including its time as part of Abbott Labs. The payout is up almost 333% since 2013, while the stock has gained roughly 676%. Growth looks set to continue. Humira's successors, Skyrizi and Rinvoq, are on track for combined 2026 sales of over $29 billion, against Humira's peak of about $22 billion in 2021. If dividend growth matches the past five years' pace, yield on cost could top 4.6% within 10 years. Consensus analyst targets imply only about 5% upside over 12 months.